

# Libtayo

**Generic Name:** cemiplimab-rwlc

**Drug Class:** [Immunotherapy Medications](#)

**Company:** Regeneron/ Sanofi

**Approval Status:** Approved

**Generic Version Available:** No

## Drug Indication

Libtayo is a checkpoint inhibitor approved for two types of skin cancer, metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, and for advanced or metastatic non-small-cell lung cancer with high PD-L1 expression.

## General Info



Libtayo is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-1 receptor on T cells. PD-1 plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and its binding partner, known as PD-L1, can release the brakes and restore T-cell activity against cancer.

Clinical trials showed that Libtayo led to complete or partial tumor shrinkage in a quarter to a half

of skin cancer patients. Responses were generally durable for at least six months. and 37% of lung cancer patients. For those with non-small-cell lung cancer, the overall response rate was 37%, and progression-free and overall survival improved compared with chemotherapy.

---

## Dosage

### **Dosing Info:**

Libtayo is administered as an intravenous infusion once every three weeks until disease progression or unacceptable side effects occur.

---

## Side Effects

Common side effects include fatigue, skin rash and diarrhea. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs, heart, liver, intestines, skin and hormone-producing endocrine glands.

---

For More Info: <https://www.libtayohcp.com/>

Co-Pay Program Info: <https://www.libtayohcp.com/>

Patient Assistance Program Info: <https://www.libtayohcp.com/>

Last Reviewed: February 24, 2021

---

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.cancerhealth.com/drug/libtayo-cemiplimab-rwlc>